CANCER:

Non Small Cell Lung Cancer

Related cancers:

‹

Lung Adenocarcinoma (350)

Lung Non-Small Cell Squamous Cancer (68)

Lung Non-Squamous Non-Small Cell Cancer (64)

Lung Adenocarcinoma (350)

Lung Non-Small Cell Squamous Cancer (68)

Lung Non-Squamous Non-Small Cell Cancer (64)

›

EML4-ALK fusion EML4-ALK fusion	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	brigatinib Sensitive: C4 – Case Studies Onco Targets Ther - 1 day
EML4-ALK fusion + ALK G1202R EML4-ALK fusion + ALK G1202R	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	lorlatinib Sensitive: C4 – Case Studies Onco Targets Ther - 1 day
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	lorlatinib Sensitive: A1 - Approval Korea Biomedical Review - 5 days
EGFR exon 19 mutation EGFR exon 19 mutation	Non Small Cell Lung Cancer NSCLC	icotinib Sensitive: B - Late Trials Respiratory Medicine - 2 weeks
EGFR exon 21 mutation EGFR exon 21 mutation	Non Small Cell Lung Cancer NSCLC	icotinib Sensitive: B - Late Trials Respiratory Medicine - 2 weeks
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	PD1 inhibitor + Angiogenesis inhibitor Sensitive: C3 – Early Trials Thorac Cancer - 2 weeks
BRAF V600 BRAF V600	Lung Adenocarcinoma LUAD	trametinib + dabrafenib + osimertinib Sensitive: C4 – Case Studies Lung Cancer - 2 weeks
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Front Oncol - 3 weeks
ROS1 mutation ROS1 mutation	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Front Oncol - 3 weeks
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Front Oncol - 3 weeks
ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Front Oncol - 3 weeks
EGFR exon 21 mutation EGFR exon 21 mutation	Non Small Cell Lung Cancer NSCLC	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Front Oncol - 3 weeks
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	bevacizumab + icotinib Sensitive: C3 – Early Trials Thorac Cancer - 3 weeks
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	X-396 Sensitive: C3 – Early Trials J Thorac Oncol - 3 weeks
EGFR exon 18-25 duplication EGFR exon 18-25 duplication	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: C4 – Case Studies Thorac Cancer - 3 weeks
EGFR exon 18-25 duplication EGFR exon 18-25 duplication	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: C4 – Case Studies Anticancer Drugs - 3 weeks
HER-2 mutation HER-2 mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: C3 – Early Trials J Thorac Oncol - 4 weeks
STRN-ALK fusion + EML4-ALK fusion + EGFR T790M STRN-ALK fusion + EML4-ALK fusion + EGFR T790M	Lung Adenocarcinoma LUAD	crizotinib + osimertinib Sensitive: C4 – Case Studies Anticancer Drugs - 4 weeks
MTOR L1433S + EGFR L858R + T790M MTOR L1433S + EGFR L858R + T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: D – Preclinical J Thorac Oncol - 4 weeks
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	ramucirumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval
ALK fusion ALK fusion	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval
KRAS G12C KRAS G12C	Non Small Cell Lung Cancer NSCLC	sotorasib Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	osimertinib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	brigatinib Sensitive: A1 - Approval
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	tepotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	lazertinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	capmatinib Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	cemiplimab Sensitive: A1 - Approval
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	pralsetinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	cisplatin + pemetrexed Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	gefitinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A1 - Approval
RET fusion RET fusion	Non Small Cell Lung Cancer NSCLC	selpercatinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: A1 - Approval
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	durvalumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	tislelizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	DP Sensitive: A1 - Approval
MET exon 14 mutation MET exon 14 mutation	Non Small Cell Lung Cancer NSCLC	savolitinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	dacomitinib Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Zirabev (bevacizumab biosimilar) Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	cisplatin + pemetrexed Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval
No biomarker No biomarker	Lung Adenocarcinoma LUAD	nintedanib Sensitive: A1 - Approval
EGFR expression EGFR expression	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	necitumumab Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	bevacizumab + atezolizumab Sensitive: A1 - Approval
BRAF V600E BRAF V600E	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval
EGFR exon 20 insertion EGFR exon 20 insertion	Non Small Cell Lung Cancer NSCLC	amivantamab-vmjw Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	docetaxel Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	afatinib Sensitive: A1 - Approval
EGFR T790M EGFR T790M	Non Small Cell Lung Cancer NSCLC	almonertinib Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	bevacizumab + erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	pembrolizumab Sensitive: A1 - Approval
EGFR exon 19 deletion EGFR exon 19 deletion	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	erlotinib + Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
ALK mutation ALK mutation	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: A1 - Approval
EGFR L858R EGFR L858R	Non Small Cell Lung Cancer NSCLC	erlotinib + ramucirumab Sensitive: A1 - Approval
ROS1 positive ROS1 positive	Non Small Cell Lung Cancer NSCLC	entrectinib Sensitive: A1 - Approval
BRAF V600 BRAF V600	Non Small Cell Lung Cancer NSCLC	trametinib + dabrafenib Sensitive: A1 - Approval
ALK positive ALK positive	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	afatinib Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	tislelizumab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval
ALK mutation ALK mutation	Lung Non-Squamous Non-Small Cell Cancer Lung Non-Squamous Non-Small Cell Cancer	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Bevax (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Non Small Cell Lung Cancer NSCLC	Krabeva (bevacizumab biosimilar) Sensitive: A1 - Approval
No biomarker No biomarker	Lung Non-Small Cell Squamous Cancer Lung Non-Small Cell Squamous Cancer	sintilimab Sensitive: A1 - Approval
EGFR mutation EGFR mutation	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline
PD-L1 expression PD-L1 expression	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: A2 - Guideline
EGFR mutation + ALK negative + TMB-H EGFR mutation + ALK negative + TMB-H	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline
ROS1 fusion ROS1 fusion	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	ceritinib Sensitive: A2 - Guideline
ROS1 rearrangement ROS1 rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline
PD-L1 overexpression PD-L1 overexpression	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	crizotinib Sensitive: A2 - Guideline
ALK rearrangement ALK rearrangement	Non Small Cell Lung Cancer NSCLC	alectinib Sensitive: A2 - Guideline

Non Small Cell Lung Cancer

Associations(2053)

Associations
(2053)